Black Diamond Therapeutics (BDTX)

Executive Summary

Black Diamond Therapeutics is a clinical-stage biopharmaceutical company pioneering MasterKey therapies designed to target genetically defined patient populations in non-small cell lung cancer (NSCLC) and glioblastoma (GBM). Its proprietary platform focuses on allosteric inhibitors that overcome resistance, minimize wild-type mediated toxicities, and achieve brain penetration to address central nervous system (CNS) disease. The company's lead program, BDTX-1535, targets EGFR and HER2 exon 20 insertions and other mutations in NSCLC, while BDTX-4933 targets KRAS mutations in solid tumors. Both candidates are designed to inhibit mutant forms while sparing wild-type, potentially improving tolerability. Black Diamond's strategy leverages tumor genetics to expand patient eligibility and address resistance mechanisms. With a focus on high unmet need and a differentiated approach, the company is positioned to deliver value in precision oncology. However, it remains early-stage with no approved products, and execution risk is tied to clinical data readouts and regulatory progress.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase 1/2 data for BDTX-1535 in EGFR-mutant NSCLC40% success
• Q4 2026Phase 1 data for BDTX-4933 in KRAS-mutant solid tumors35% success